Discovery of potent imidazole and cyanophenyl containing farnesyltransferase inhibitors with improved oral bioavailability.
Tong, Y., Lin, N.H., Wang, L., Hasvold, L., Wang, W., Leonard, N., Li, T., Li, Q., Cohen, J., Gu, W.Z., Zhang, H., Stoll, V., Bauch, J., Marsh, K., Rosenberg, S.H., Sham, H.L.(2003) Bioorg Med Chem Lett 13: 1571-1574
- PubMed: 12699757 Search on PubMed
- DOI: https://doi.org/10.1016/s0960-894x(03)00195-1
- Primary Citation Related Structures: 
1NI1 - PubMed Abstract: 
A pyridyl moiety was introduced into a previously developed series of farnesyltransferase inhibitors containing imidazole and cyanophenyl (such as 4), resulting in potent inhibitors with improved pharmacokinetics.
- R47B, AP10, Global Pharmaceutical R&D, Abbott Laboratories, 100 Abbott Park Road, Abbott Park, IL 60064-6101, USA. yunsong.tong@abbott.com
Organizational Affiliation: 

















